$AMPL News

Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases

The Top 5 Analyst Questions From Amplitude’s Q2 Earnings Call

Morgan Stanley Maintains Overweight on Amplitude, Raises Price Target to $16

Amplitude (AMPL) Q2 2026 Earnings Call Transcript

Amplitude Conference: CFO Sees Platform, Enterprise Push and AI Fueling Growth

Amplitude to Present at Upcoming Investor Conferences

Is Amplitude (AMPL) Undervalued After Its Earnings Beat And New Guidance?

Citigroup Maintains Neutral on Amplitude, Raises Price Target to $11

Amplitude Inc (AMPL) (Q2 2026) Earnings Call Highlights: AI-Native Transformation Drives 21% ...

DA Davidson Maintains Buy on Amplitude, Raises Price Target to $12.5

Amplitude, Inc. 2026 Q2 - Results - Earnings Call Presentation

Klaviyo Demand Remains Resilient, Statsig Drives Amplitude Growth, ZoomInfo Recovery Still Unproven, Morgan Stanley Says

NTTYY or AMPL: Which Is the Better Value Stock Right Now?

UBS Maintains Buy on Amplitude, Raises Price Target to $13

BTIG Maintains Buy on Amplitude, Raises Price Target to $13

Piper Sandler Maintains Overweight on Amplitude, Raises Price Target to $13

Amplitude, Inc. (AMPL) Q2 2026 Earnings Call Transcript

Amplitude, Inc. (AMPL) Reports Q2 Loss, Tops Revenue Estimates

Amplitude (AMPL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Amplitude Q2 Earnings Call Highlights